GlobeNewswire: BioMarin Pharmaceutical Inc. Contains the last 10 of 243 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T17:53:32ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2016/12/12/896825/0/en/BioMarin-Enrolls-First-Participant-in-Phase-3-Trial-of-Vosoritide-for-Treatment-of-Children-with-Achondroplasia.html?f=22&fvtc=4&fvtv=14233BioMarin Enrolls First Participant in Phase 3 Trial of Vosoritide for Treatment of Children with Achondroplasia2016-12-12T13:29:00Z<![CDATA[SAN RAFAEL, Calif., Dec. 12, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company has initiated a global Phase 3 study for vosoritide, an analog of C-type Natriuretic Peptide (CNP), in children with achondroplasia, the most common form of dwarfism. The first child enrolled in the study was at a site in Australia.]]>https://www.globenewswire.com/news-release/2016/11/03/886313/0/en/BioMarin-to-Attend-Three-Upcoming-Investor-Conferences.html?f=22&fvtc=4&fvtv=14233BioMarin to Attend Three Upcoming Investor Conferences2016-11-03T12:30:00Z<![CDATA[- Credit Suisse 25th Annual Healthcare Conference on November 7 in Scottsdale, Arizona]]>https://www.globenewswire.com/news-release/2016/10/27/883855/0/en/BioMarin-Announces-Third-Quarter-2016-Financial-Results.html?f=22&fvtc=4&fvtv=14233BioMarin Announces Third Quarter 2016 Financial Results2016-10-27T20:03:00Z<![CDATA[- Third Quarter 2016 Total BioMarin Revenues Increase 34% Year over Year to $280 million]]>https://www.globenewswire.com/news-release/2016/10/19/880926/0/en/BioMarin-Presents-Vosoritide-Data-in-Achondroplasia-at-American-Society-of-Human-Genetics-ASHG-2016-Meeting.html?f=22&fvtc=4&fvtv=14233BioMarin Presents Vosoritide Data in Achondroplasia at American Society of Human Genetics (ASHG) 2016 Meeting2016-10-19T21:01:00Z<![CDATA[Highest Dose (30 µg/kg/day) Shows Approximately 50% Increase in Mean Annualized Growth Velocity, Comparable with 15 µg/kg/day dose]]>https://www.globenewswire.com/news-release/2016/10/13/879403/0/en/UK-Regulatory-Agency-Approves-Continued-Enrollment-in-BioMarin-Phase-1-2-Study-of-BMN-270-in-Hemophilia-A.html?f=22&fvtc=4&fvtv=14233UK Regulatory Agency Approves Continued Enrollment in BioMarin Phase 1/2 Study of BMN 270 in Hemophilia A2016-10-13T20:01:00Z<![CDATA[Phase 1/2 Study Expected to Resume by End of 2016]]>https://www.globenewswire.com/news-release/2016/10/11/878558/0/en/BioMarin-to-Host-Third-Quarter-2016-Financial-Results-Conference-Call-and-Webcast-on-Thursday-October-27-at-4-30pm-ET.html?f=22&fvtc=4&fvtv=14233BioMarin to Host Third Quarter 2016 Financial Results Conference Call and Webcast on Thursday, October 27 at 4:30pm ET2016-10-11T12:30:00Z<![CDATA[SAN RAFAEL, Calif., Oct. 11, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, October 27, at 4:30 p.m. ET to discuss third quarter 2016 financial results and provide a general business update.]]>https://www.globenewswire.com/news-release/2016/09/21/873522/0/en/BioMarin-Reviews-Status-of-Exon-51-Composition-of-Matter-and-Method-of-Use-Patent-Interference-Cases-against-Sarepta-Therapeutics.html?f=22&fvtc=4&fvtv=14233BioMarin Reviews Status of Exon 51 Composition of Matter and Method of Use Patent Interference Cases against Sarepta Therapeutics2016-09-21T12:53:46Z<![CDATA[BioMarin to Seek Review of Ruling in Composition of Matter Patent Interference (No. 106,008)]]>https://www.globenewswire.com/news-release/2016/09/15/872131/0/en/BioMarin-Announces-EMA-Validation-of-Brineura-Cerliponase-Alfa-Marketing-Authorization-Application-for-Treatment-of-CLN2-Disease-a-Form-of-Batten-Disease.html?f=22&fvtc=4&fvtv=14233BioMarin Announces EMA Validation of Brineura™ (Cerliponase Alfa) Marketing Authorization Application for Treatment of CLN2 Disease, a Form of Batten Disease2016-09-15T12:37:45Z<![CDATA[CHMP Opinion and EU Decision Expected Q3 2017 CHMP Opinion and EU Decision Expected Q3 2017]]>https://www.globenewswire.com/news-release/2016/09/08/870391/0/en/BioMarin-Announces-Two-Oral-and-16-Poster-Presentations-at-Society-for-the-Study-of-Inborn-Errors-of-Metabolism-2016-Annual-Meeting.html?f=22&fvtc=4&fvtv=14233BioMarin Announces Two Oral and 16 Poster Presentations at Society for the Study of Inborn Errors of Metabolism 2016 Annual Meeting2016-09-08T08:30:00Z<![CDATA[Oral Presentations Include Updated Long-Term Data from Extension Study of Brineura™ (Cerliponase Alfa) in Children with CLN2 Disease, and Long-Term Safety and Efficacy Data of Pegvaliase in Adults with PKU Oral Presentations Include Updated Long-Term Data from Extension Study of Brineura™ (Cerliponase Alfa) in Children with CLN2 Disease, and Long-Term Safety and Efficacy Data of Pegvaliase in Adults with PKU]]>https://www.globenewswire.com/news-release/2016/09/06/869879/0/en/BioMarin-Announces-Update-to-Brineura-Cerliponase-Alfa-Program-for-Treatment-of-CLN2-Disease-a-Form-of-Batten-Disease.html?f=22&fvtc=4&fvtv=14233BioMarin Announces Update to Brineura™ (Cerliponase Alfa) Program for Treatment of CLN2 Disease, a Form of Batten Disease2016-09-06T20:05:00Z<![CDATA[Additional Data Submitted to BLA following FDA Request, PDUFA Action Date Extended to April 27, 2017]]>